Form 144 Hims & Hers Health, Inc. Filed by: Chi Michael
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Piper Sandler Reiterates Neutral Rating on Hims and Hers (HIMS), PT $24
February 21, 2025 12:23 PM ESTPiper Sandler analyst Korinne Wolfmeyer reiterated a Neutral rating and $24.00 price target on Hims and Hers (NYSE: HIMS)
The analyst comments "We believe it's best to remain on the sidelines with HIMS following the FDA's announcement this morning that... More
Why Morgan Stanley is cautious on Hims & Hers shares
February 20, 2025 4:00 PM ESTMorgan Stanley remains cautious on Hims & Hers Health, Inc. (NYSE: HIMS) despite the companys latest move into at-home lab testing through its acquisition of Trybe Labs.
The investment bank maintains an Equal-weight rating on the stock, arguing that excitement around the companys growth potential may be outpacing realistic financial... More
Hims and Hers (HIMS) PT Raised to $21 at BofA Securities
February 20, 2025 5:18 AM ESTBofA Securities analyst Michael Cherny raised the price target on Hims and Hers (NYSE: HIMS) to $21.00 (from $18.00) while maintaining a Underperform rating.
The analyst comments "HIMS observed sales per Bloomberg Second Measure (BSM) data grew 104% y/y in January and suggests GLP-1s... More
